Albert Hsia is Executive Director, Business Development at Merck where he leads Oncology and Immunology business development at Merck’s Boston Hub, focusing on partnership and M&A opportunities to accelerate the development of innovative medicines. Albert brings over two decades of biopharma business and corporate development experience, including eight years at Merck and, prior to Merck, at Disarm Therapeutics (now Lilly), Atlas Venture, Genewave (now Hologic), and Synta Pharmaceuticals (now Madrigal Pharmaceuticals). He holds a Ph.D. from U.C. San Francisco and a B.A. from Harvard University.